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Issue one of the second volume of Therapeutics and Clinical Risk Management
presents a range of review articles from internationally recognised authors, each of
whom addresses an important and apposite topic in the therapeutic management of
clinical risk.
Overactive bladder (OAB) and urinary incontinence are prevalent and distressing
conditions with significant associated direct and indirect economic costs. Moreover,
the majority of OAB patients do not present for treatment in spite of a considerable
reduction in mental health and health-related quality of life. Antimuscarinic agents
have been at the forefront of therapy for OAB for 30 years; however, patient
compliance rates are extremely poor as a result of drug expenses, suboptimal dosage
regimens, a commonly incomplete improvement in symptoms, and intolerable
systemic side-effects. McCrery and Appell review the latest alternative drug delivery
systems for the antimuscarinic agent, oxybutynin chloride (OXY), including OXY-
ER, an extended-release formulation, and OXY-TDS, a transdermal system, together
with a range of other antimuscarinic agents.
The worldwide prevalence of asthma has increased to approximately 300 million
and represents a major socioeconomic and healthcare load. The established efficacy
of inhaled corticosteroids (ICS) has resulted in their being promoted as the cornerstone
of asthma therapy. However, local and systemic adverse effects can limit their use
and result in significantly reduced compliance. Ronald Dahl presents a comprehensive
review of ciclesonide, a nonhalogenated corticosteroid that demonstrates potent anti-
inflammatory activity with similar efficacy to other ICS in asthma and did not elicit
unfavorable side effects at dosages used in clinical trials. This knowledge may enhance
the management of this prevalent condition in which poor compliance to prescribed
medication is common.
The number of liver transplants secondary to hepatitis viruses has risen
substantially over the past 20 years in Europe and the US. Approximately 50% are
due to infection with hepatitis C virus (HCV) and projections suggest that the impact
on public health will continue to increase. Picciotto reviews the natural history of
HCV patients following transplant and the available therapeutic options, for which
there is as yet no consensus. Post-transplant clinical sequelae are characterized in
most patients by HCV reinfection and development of chronic hepatitis. Therapeutic
strategies for the management of HCV during the peri-transplant phase include
pretransplant prophylaxis to prevent the transplanted organ becoming infected; post-
transplant prophylaxis to attenuate risk of acute hepatitis; and management of the
stablized chronic disease state.
Musculoskeletal conditions, including rheumatoid arthritis (RA) and osteoarthritis
(OA) amongst others, represent a significant burden in terms of socioeconomic cost
and morbidity. Although nonsteroidal antiinflammatory drugs (NSAIDs) play an
important role in the management of RA and OA, their longer-term use is associated
with considerable upper gastrointestinal symptoms that contribute to poor compliance
and inadequate control of inflammation and pain. Etoricoxib is a selective COX-2
inhibitor, a subclass of NSAIDs that demonstrate comparable clinical efficacy to
traditional NSAIDs together with significantly reduced gastrointestinal toxicity. The
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and summarizes the current clinical data on its efficacy,
tolerability, and patient acceptability.
Zhanel and colleagues examine the role of telithromycin,
the first ketolide antibiotic to gain US Food and Drug
Administration (FDA)-approval for the treatment of acute
bacterial sinusitis, acute exacerbations of chronic bronchitis,
and community-acquired pneumonia in adult outpatients.
Collectively, these three conditions are responsible for
significant morbidity and substantial socioeconomic costs.
The authors present a review of the mechanisms by which
telithromycin exerts its antibacterial activity and also assess
the pharmacokinetic and pharmacodynamic properties,
clinical efficacy, and tolerability-safety profiles.
The increasing prevalence of osteoporosis worldwide
contributes significantly to morbidity and mortality amongst
our aging populations with considerable attendant health
and financial implications. In the first of two complementary
reviews examining the primary role of the bisphosphonates
in the management of osteoporosis, Bauss and Schimmer
comprehensively review the efficacy and safety of
ibandronate, a highly potent N-containing bisphosphonate
that combines the known efficacy of this drug class with
enhanced safety and tolerability profiles. Grey and Reid use
the limited available data to critically evaluate the differences
between agents of this expanding class of drugs in terms of
potency, administration route, duration of action, and
efficacy. Bisphosphonates demonstrate a high antiresorptive
potency that allows lower doses and extended dosing
intervals and has recently been approved as the first once-
monthly oral drug for the treatment and prevention of
postmenopausal osteoporosis in the US.
Larkin and Eisen report that incidence of renal cell
carcinoma (RCC) in the UK increased by almost 20%
between 1991 and 2000. In cases of metastatic RCC, whilst
immunotherapy may offer a small overall increase in
survival, it does not benefit the majority of patients and there
is thus a need to elucidate new therapeutic approaches.
Sorafenib is an orally administered, novel member of the
kinase inhibitor class of drugs. In phase 2 studies amongst
patients with RCC pretreated with immunotherapy, it has
demonstrated significant activity with manageable toxicity
while a phase 3 study has shown prolonged progression-
free survival when compared with placebo.
In the second of our two complementary reviews,
Tadicherla and Berman examine the role of noninvasive
percutaneous drug delivery systems used in the local control
of pain. They outline the mechanisms of percutaneous
absorption of these products and address their composition,
duration of onset of anesthetic effect, and uses and side
effects. The authors also discuss novel advances in the use
of heat to enhance anesthetic penetration, as provided by
the SyneraTM patch, and use of a peel method to deliver
anesthesia, such as that provided by S-Caine patch, a product
that is currently awaiting FDA approval. The opioid class
of analgesics has proven efficacy and a long history of use
in the management of both acute and chronic pain; however,
concerns over their safety, tolerability and longer-term
acceptance to patients have prevented them from realising
their therapeutic promise. Rudolf Likar presents a review
of the safety aspects of the transdermal semisynthetic opioid
buprenorphine and highlights the results of two decades’
work that indicates its superior therapeutic benefits and
safety profile.